Lack of in vivo mutagenicity of carbendazim in the liver and glandular stomach of MutaMice
Abstract Background Carbendazim (methyl 2-benzimidazolecarbamate, CASRN: 10605-21-7) exhibits spindle poisoning effects and is widely used as a fungicide. With respect to genotoxicity, carbendazim is deemed to be non-mutagenic in vitro, but it causes indicative DNA damage in vivo and chromosome aber...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | Genes and Environment |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41021-024-00299-4 |
| _version_ | 1797273276146253824 |
|---|---|
| author | Takako Iso Kenichiro Suzuki Yasumasa Murata Nozomu Hirose Takaaki Umano Katsuyoshi Horibata Kei-ichi Sugiyama Akihiko Hirose Kenichi Masumura Mariko Matsumoto |
| author_facet | Takako Iso Kenichiro Suzuki Yasumasa Murata Nozomu Hirose Takaaki Umano Katsuyoshi Horibata Kei-ichi Sugiyama Akihiko Hirose Kenichi Masumura Mariko Matsumoto |
| author_sort | Takako Iso |
| collection | DOAJ |
| description | Abstract Background Carbendazim (methyl 2-benzimidazolecarbamate, CASRN: 10605-21-7) exhibits spindle poisoning effects and is widely used as a fungicide. With respect to genotoxicity, carbendazim is deemed to be non-mutagenic in vitro, but it causes indicative DNA damage in vivo and chromosome aberrations in vitro and in vivo. In this study, we examined the mutagenicity of carbendazim in vivo. Results MutaMice were treated with carbendazim orally at doses of 0 (corn oil), 250, 500, and 1,000 mg/kg/day once a day for 28 days. A lacZ assay was used to determine the mutant frequency (MF) in the liver and glandular stomach of mice. MutaMice were administered up to the maximum dose recommended by the Organization for Economic Co-operation and Development Test Guidelines for Chemicals No. 488 (OECD TG488). The lacZ MFs in the liver and glandular stomach of carbendazim-treated animals were not significantly different from those in the negative control animals. In contrast, positive control animals exhibited a significant increase in MFs in both the liver and glandular stomach. Conclusions Carbendazim is non-mutagenic in the liver and glandular stomach of MutaMice following oral treatment. |
| first_indexed | 2024-03-07T14:41:11Z |
| format | Article |
| id | doaj.art-d173ef94bfb2421bb06ba6963778978e |
| institution | Directory Open Access Journal |
| issn | 1880-7062 |
| language | English |
| last_indexed | 2024-03-07T14:41:11Z |
| publishDate | 2024-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Genes and Environment |
| spelling | doaj.art-d173ef94bfb2421bb06ba6963778978e2024-03-05T20:22:30ZengBMCGenes and Environment1880-70622024-02-014611810.1186/s41021-024-00299-4Lack of in vivo mutagenicity of carbendazim in the liver and glandular stomach of MutaMiceTakako Iso0Kenichiro Suzuki1Yasumasa Murata2Nozomu Hirose3Takaaki Umano4Katsuyoshi Horibata5Kei-ichi Sugiyama6Akihiko Hirose7Kenichi Masumura8Mariko Matsumoto9Division of Risk Assessment, National Institute of Health SciencesGenotoxicology Laboratory, BioSafety Research Center Inc.Division of Risk Assessment, National Institute of Health SciencesDivision of Risk Assessment, National Institute of Health SciencesDivision of Risk Assessment, National Institute of Health SciencesDivision of Genetics and Mutagenesis, National Institute of Health SciencesDivision of Genetics and Mutagenesis, National Institute of Health SciencesDivision of Risk Assessment, National Institute of Health SciencesDivision of Risk Assessment, National Institute of Health SciencesDivision of Risk Assessment, National Institute of Health SciencesAbstract Background Carbendazim (methyl 2-benzimidazolecarbamate, CASRN: 10605-21-7) exhibits spindle poisoning effects and is widely used as a fungicide. With respect to genotoxicity, carbendazim is deemed to be non-mutagenic in vitro, but it causes indicative DNA damage in vivo and chromosome aberrations in vitro and in vivo. In this study, we examined the mutagenicity of carbendazim in vivo. Results MutaMice were treated with carbendazim orally at doses of 0 (corn oil), 250, 500, and 1,000 mg/kg/day once a day for 28 days. A lacZ assay was used to determine the mutant frequency (MF) in the liver and glandular stomach of mice. MutaMice were administered up to the maximum dose recommended by the Organization for Economic Co-operation and Development Test Guidelines for Chemicals No. 488 (OECD TG488). The lacZ MFs in the liver and glandular stomach of carbendazim-treated animals were not significantly different from those in the negative control animals. In contrast, positive control animals exhibited a significant increase in MFs in both the liver and glandular stomach. Conclusions Carbendazim is non-mutagenic in the liver and glandular stomach of MutaMice following oral treatment.https://doi.org/10.1186/s41021-024-00299-4CarbendazimIn vivo mutagenicityTransgenic rodent gene mutation assay |
| spellingShingle | Takako Iso Kenichiro Suzuki Yasumasa Murata Nozomu Hirose Takaaki Umano Katsuyoshi Horibata Kei-ichi Sugiyama Akihiko Hirose Kenichi Masumura Mariko Matsumoto Lack of in vivo mutagenicity of carbendazim in the liver and glandular stomach of MutaMice Genes and Environment Carbendazim In vivo mutagenicity Transgenic rodent gene mutation assay |
| title | Lack of in vivo mutagenicity of carbendazim in the liver and glandular stomach of MutaMice |
| title_full | Lack of in vivo mutagenicity of carbendazim in the liver and glandular stomach of MutaMice |
| title_fullStr | Lack of in vivo mutagenicity of carbendazim in the liver and glandular stomach of MutaMice |
| title_full_unstemmed | Lack of in vivo mutagenicity of carbendazim in the liver and glandular stomach of MutaMice |
| title_short | Lack of in vivo mutagenicity of carbendazim in the liver and glandular stomach of MutaMice |
| title_sort | lack of in vivo mutagenicity of carbendazim in the liver and glandular stomach of mutamice |
| topic | Carbendazim In vivo mutagenicity Transgenic rodent gene mutation assay |
| url | https://doi.org/10.1186/s41021-024-00299-4 |
| work_keys_str_mv | AT takakoiso lackofinvivomutagenicityofcarbendazimintheliverandglandularstomachofmutamice AT kenichirosuzuki lackofinvivomutagenicityofcarbendazimintheliverandglandularstomachofmutamice AT yasumasamurata lackofinvivomutagenicityofcarbendazimintheliverandglandularstomachofmutamice AT nozomuhirose lackofinvivomutagenicityofcarbendazimintheliverandglandularstomachofmutamice AT takaakiumano lackofinvivomutagenicityofcarbendazimintheliverandglandularstomachofmutamice AT katsuyoshihoribata lackofinvivomutagenicityofcarbendazimintheliverandglandularstomachofmutamice AT keiichisugiyama lackofinvivomutagenicityofcarbendazimintheliverandglandularstomachofmutamice AT akihikohirose lackofinvivomutagenicityofcarbendazimintheliverandglandularstomachofmutamice AT kenichimasumura lackofinvivomutagenicityofcarbendazimintheliverandglandularstomachofmutamice AT marikomatsumoto lackofinvivomutagenicityofcarbendazimintheliverandglandularstomachofmutamice |